Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Angus Wilfong

Neurology with Special Qualifications in Child Neurology Phoenix, AZ Medical Doctor

NPI 1629158977 CMS profile 28837

1919 E Thomas Rd, Phoenix, AZ 85016

Open in the dashboard

General payments

$348,359

361 records reported · program years 2019–2025

Research payments

$2,608

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$359,369 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Angus Wilfong of Phoenix, AZ is reported in the CMS Open Payments database as having received $348,359 across 361 general payments and $2,608 in research payments paid to them. Separately, studies naming them as principal investigator received $359,369 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,507 31
2024 General $27,331 32
2023 General $66,835 68
2022 General $58,654 64
2021 General $33,804 35
2020 General $30,328 36
2020 Research $2,608 2
2019 General $84,901 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angus Wilfong
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Angus Wilfong were reported at $46,507. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Angus Wilfong Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $84,901 $262 $68–$1,313 $163
2020 $30,328 $188 $46–$1,222 $114
2021 $33,804 $183 $45–$1,356 $132
2022 $58,654 $229 $72–$1,177 $149
2023 $66,835 $269 $93–$1,195 $160
2024 $27,331 $300 $98–$1,428 $164
2025 $46,507 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LivaNova USA, Inc. $292,035 263 payments
  2. Sunovion Pharmaceuticals Inc. $17,730 34 payments
  3. Greenwich Biosciences, Inc. $17,245 14 payments
  4. UCB, Inc. $7,931 21 payments
  5. Neurelis, Inc. $6,138 8 payments
  6. SK Life Science, Inc. $4,865 7 payments
  7. Zogenix Inc. $1,400 1 payment
  8. NeuroPace, Inc. $540 3 payments
  9. Medtronic USA, Inc. $380 3 payments
  10. Sumitomo Pharma America, Inc. $47 4 payments
  11. Other $47 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $237,309 94 payments
  2. Travel and Lodging $42,608 134 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $32,904 17 payments
  4. Consulting Fee $15,421 10 payments
  5. Food and Beverage $10,008 100 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,100 3 payments
  7. Honoraria $5,008 2 payments
  8. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. VNS THERAPY SENTIVA MODEL 1000 GENERATOR Cardiology/Vascular Diseases $103,631 70 payments
  2. VNS Therapy Cardiology/Vascular Diseases $87,684 107 payments
  3. VNS THERAPY SENTIVA MODEL 1000 GENERATOR Neurology $63,702 34 payments
  4. VNS - Sentiva $28,217 28 payments
  5. APTIOM $17,341 33 payments
  6. Epidiolex $17,245 14 payments
  7. VNS Therapy Neurology $8,801 24 payments
  8. Briviact $7,050 19 payments
  9. VALTOCO $5,581 7 payments
  10. Fintepla $1,400 1 payment
  11. Other $2,317 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. LivaNova USA, Inc. $1,800 1 payment
  2. Medtronic USA, Inc. $808 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

27

Median for Neurology: 833

Drug cost

$65,726

Median for Neurology: $202,670

Branded share of claims

100%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xcopri Cenobamate Brand 15 $34,979
Lamictal Odt Lamotrigine Brand 12 $30,747

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VALTOCO
  • Neurelis, Inc. $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record